Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Acronyms POSEIDON
- Sponsors Aimmune Therapeutics
- 02 Aug 2019 Planned number of patients changed to 132.
- 19 Dec 2018 According to an Aimmune Therapeutics media release, Brian Vickery, M.D., Associate Professor of Pediatrics at Emory University and Founding Director of the Food Allergy Center at Children's Healthcare of Atlanta, member of the Aimmune Scientific Advisory Board, is the Principal Investigator for the POSEIDON trial.
- 17 Nov 2018 New trial record